CN107375505A - 一种预防和治疗眼部疾病的组合物及其制备方法与应用 - Google Patents
一种预防和治疗眼部疾病的组合物及其制备方法与应用 Download PDFInfo
- Publication number
- CN107375505A CN107375505A CN201710696456.XA CN201710696456A CN107375505A CN 107375505 A CN107375505 A CN 107375505A CN 201710696456 A CN201710696456 A CN 201710696456A CN 107375505 A CN107375505 A CN 107375505A
- Authority
- CN
- China
- Prior art keywords
- parts
- powder
- eye disease
- composition
- prevention
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000030533 eye disease Diseases 0.000 title claims abstract description 46
- 239000000203 mixture Substances 0.000 title claims abstract description 42
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- 239000000843 powder Substances 0.000 claims abstract description 49
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 32
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 32
- 230000002265 prevention Effects 0.000 claims abstract description 25
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 20
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims abstract description 20
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 20
- 239000003094 microcapsule Substances 0.000 claims abstract description 18
- 235000004347 Perilla Nutrition 0.000 claims abstract description 11
- 240000000851 Vaccinium corymbosum Species 0.000 claims abstract description 11
- 235000003095 Vaccinium corymbosum Nutrition 0.000 claims abstract description 11
- 235000017537 Vaccinium myrtillus Nutrition 0.000 claims abstract description 11
- 235000021014 blueberries Nutrition 0.000 claims abstract description 11
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 11
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 10
- 235000012680 lutein Nutrition 0.000 claims abstract description 10
- 229960005375 lutein Drugs 0.000 claims abstract description 10
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims abstract description 10
- 239000001656 lutein Substances 0.000 claims abstract description 10
- 235000020733 paullinia cupana extract Nutrition 0.000 claims abstract description 10
- 239000001335 perilla frutescens leaf extract Substances 0.000 claims abstract description 10
- 229960003080 taurine Drugs 0.000 claims abstract description 10
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims abstract description 10
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 10
- 239000011718 vitamin C Substances 0.000 claims abstract description 10
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims abstract description 10
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims abstract description 9
- 235000016357 Mirtillo rosso Nutrition 0.000 claims abstract description 9
- 244000077923 Vaccinium vitis idaea Species 0.000 claims abstract description 9
- 235000017606 Vaccinium vitis idaea Nutrition 0.000 claims abstract description 9
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims abstract description 9
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims abstract description 9
- 235000013305 food Nutrition 0.000 claims abstract description 9
- 239000003921 oil Substances 0.000 claims abstract description 9
- 235000019198 oils Nutrition 0.000 claims abstract description 9
- 239000002994 raw material Substances 0.000 claims abstract description 9
- 235000019155 vitamin A Nutrition 0.000 claims abstract description 9
- 239000011719 vitamin A Substances 0.000 claims abstract description 9
- 229940045997 vitamin a Drugs 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 8
- 230000036541 health Effects 0.000 claims abstract description 7
- KBPHJBAIARWVSC-TWGKZGRNSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=C[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-TWGKZGRNSA-N 0.000 claims abstract description 7
- 244000124853 Perilla frutescens Species 0.000 claims abstract 3
- 239000007788 liquid Substances 0.000 claims description 10
- 229920002774 Maltodextrin Polymers 0.000 claims description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
- 210000001508 eye Anatomy 0.000 claims description 9
- 235000019871 vegetable fat Nutrition 0.000 claims description 9
- 208000000655 Distemper Diseases 0.000 claims description 8
- 241000229722 Perilla <angiosperm> Species 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 235000013373 food additive Nutrition 0.000 claims description 7
- 239000002778 food additive Substances 0.000 claims description 7
- 208000002177 Cataract Diseases 0.000 claims description 6
- 239000005913 Maltodextrin Substances 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 6
- 238000005516 engineering process Methods 0.000 claims description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- 229940035034 maltodextrin Drugs 0.000 claims description 6
- 238000001694 spray drying Methods 0.000 claims description 5
- 239000000853 adhesive Substances 0.000 claims description 4
- 230000001070 adhesive effect Effects 0.000 claims description 4
- 239000000945 filler Substances 0.000 claims description 4
- 239000000314 lubricant Substances 0.000 claims description 4
- 208000002780 macular degeneration Diseases 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 108010011485 Aspartame Proteins 0.000 claims description 3
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 3
- 206010013774 Dry eye Diseases 0.000 claims description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- 208000003251 Pruritus Diseases 0.000 claims description 3
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 3
- 239000000605 aspartame Substances 0.000 claims description 3
- 235000010357 aspartame Nutrition 0.000 claims description 3
- 229960003438 aspartame Drugs 0.000 claims description 3
- 235000015165 citric acid Nutrition 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
- 230000036407 pain Effects 0.000 claims description 3
- 201000010041 presbyopia Diseases 0.000 claims description 3
- 239000004383 Steviol glycoside Substances 0.000 claims description 2
- 208000003464 asthenopia Diseases 0.000 claims description 2
- 238000007796 conventional method Methods 0.000 claims description 2
- -1 hydroxypropyl Chemical group 0.000 claims description 2
- 229930182488 steviol glycoside Natural products 0.000 claims description 2
- 235000019411 steviol glycoside Nutrition 0.000 claims description 2
- 150000008144 steviol glycosides Chemical class 0.000 claims description 2
- 235000019202 steviosides Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims 1
- 235000010980 cellulose Nutrition 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 230000007803 itching Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 14
- 150000003254 radicals Chemical class 0.000 abstract description 9
- 239000003963 antioxidant agent Substances 0.000 abstract description 7
- 230000003078 antioxidant effect Effects 0.000 abstract description 7
- 235000006708 antioxidants Nutrition 0.000 abstract description 7
- 206010061218 Inflammation Diseases 0.000 abstract description 5
- 230000004054 inflammatory process Effects 0.000 abstract description 5
- 230000002079 cooperative effect Effects 0.000 abstract description 3
- 230000007246 mechanism Effects 0.000 abstract description 3
- 230000001629 suppression Effects 0.000 abstract description 3
- 238000013329 compounding Methods 0.000 abstract 1
- 210000000695 crystalline len Anatomy 0.000 description 19
- 239000000243 solution Substances 0.000 description 15
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 239000000047 product Substances 0.000 description 7
- 230000008859 change Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 229960003180 glutathione Drugs 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- 150000003722 vitamin derivatives Chemical class 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 102000019197 Superoxide Dismutase Human genes 0.000 description 4
- 108010012715 Superoxide dismutase Proteins 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 240000003444 Paullinia cupana Species 0.000 description 3
- 235000000556 Paullinia cupana Nutrition 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 230000004792 oxidative damage Effects 0.000 description 3
- 230000036542 oxidative stress Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000002893 slag Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 235000020985 whole grains Nutrition 0.000 description 3
- 108010024636 Glutathione Proteins 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 2
- 235000011613 Pinus brutia Nutrition 0.000 description 2
- 241000018646 Pinus brutia Species 0.000 description 2
- 206010064930 age-related macular degeneration Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229910015400 FeC13 Inorganic materials 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 240000007695 Nandina domestica Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- OHJMTUPIZMNBFR-UHFFFAOYSA-N biuret Chemical compound NC(=O)NC(N)=O OHJMTUPIZMNBFR-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 210000004220 fundus oculi Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004377 microelectronic Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 150000002831 nitrogen free-radicals Chemical class 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 208000005494 xerophthalmia Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/01—Instant products; Powders; Flakes; Granules
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/535—Perilla (beefsteak plant)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种预防和治疗眼部疾病的组合物及其制备方法与应用，每100重量份包括以下重量份的原料：决明子10‑40份、蓝莓粉/越橘粉5‑30份、叶黄素酯/叶黄素/叶黄素酯微囊粉10‑30份、紫苏籽油/紫苏子油微囊粉10‑30份、磷脂1‑15份、瓜拉纳提取物1‑15份、牛磺酸0.1‑3份、维生素C 0.01‑0.5份、维生素A/β胡萝卜素0.001‑0.1份。本发明的组合物可以与辅剂复配用来制备预防和治疗眼部疾病的药物、保健品及食品。本发明的组合物通过上述几种原料的配伍，通过多种作用基理发挥功效，并且在多种功效之间产生协同效应，有效作用于机体，在抗氧化、清除自由基、抑制炎症等各方面都具有显著效果，可以用于预防和治疗各类眼部疾病。
Description
技术领域
本发明涉及一种预防和治疗眼部疾病的组合物及其制备方法与应用。
背景技术
氧化还原反应是人体最基本的生化反应，细胞膜以及细胞内分子通过氧化或还原反应，使得分子结构及功能发生改变，进而影响细胞的信号转导、基因转录等过程，对细胞生命活动产生着重要的影响。然而，当机体遭受各种有害刺激(如辐射、缺血、缺氧等)时，体内产生过多高活性分子，如活性氧自由基(ROS)和活性氮自由基(RNS)，氧化程度超出氧化物的清除，导致氧化系统和抗氧化系统失衡，从而引起组织炎症及损伤。
在身体的众多器官中，眼睛是暴露于体表的器官之一，常年受到阳光的直接照射，易受到感染等多种理化因素影响，相对的ROS、RNS产生较多，因此，眼部的许多相关疾病都与氧化应激因素密切相关。由于眼表长期暴露于体外，最易受到各种理化因素的攻击，而这众多攻击导致的共同结果是细胞内活性氧物质的增多，导致干眼症、结膜炎、角膜炎等一系列眼表疾病。白内障是眼科最常见的疾病之一，而白内障的发生发展与晶状体氧化应激有密切的联系，自由基损伤是各种致白内障因素作用的共同途径，自由基能引起的晶状体氧化损伤及生化改变，导致晶状体的混浊。另外，糖尿病视网膜病变、黄斑变性等眼底疾病都与眼底缺氧导致的自由基增多有密切的联系。
本发明针对上述现象，发挥中医饮食疗法和现代营养学各自的优势，并结合现代药理研究结果，开发出既能预防和治疗由于氧化应激引起的各类眼部疾病的组合物。本发明的组合物据有抗氧化、清除自由基、抑制炎症的作用，从眼部疾病的发病源头着手达到防治各类眼部疾病的目的。
发明内容
本发明所要解决的技术问题是针对现有技术中存在的不足，而提供一种预防和治疗眼部疾病的组合物及其制备方法与应用。本发明组合物具有抗氧化、清除自由基、抑制炎症的作用，用于白内障、青光眼、老年黄斑变性、老花眼及眼干眼涩、痒痛等眼部疾病预防和治疗。
为了实现上述目的，本发明采用如下技术方案：
本发明首先提供一种预防和治疗眼部疾病的组合物，每100重量份包括以下重量份的原料：
决明子10-40份、蓝莓粉/越橘粉5-30份、叶黄素酯/叶黄素/叶黄素酯微囊粉10-30份、紫苏籽油粉/紫苏子油微囊粉10-30份、磷脂1-15份、瓜拉纳提取物1-15份、牛磺酸0.1-3份、维生素C 0.01-0.5份、维生素A/β胡萝卜素0.001-0.1份。
上述技术方案中，所述的预防和治疗眼部疾病的组合物，每100重量份进一步优选包括以下重量份的原料：
决明子30份、蓝莓粉/越橘粉20份、叶黄素酯/叶黄素/叶黄素酯微囊粉15份、紫苏籽油粉/紫苏子油微囊粉15份、磷脂10份、瓜拉纳提取物9.4份、牛磺酸0.4份、维生素C0.195份、维生素A/β胡萝卜素0.005份。
本发明还提供一种上述的预防和治疗眼部疾病的组合物的制备方法，包括以下步骤：
(1)将所述比例的决明子放于6-15倍水中，在70-95℃下煎煮10-30min，过滤得到煎出液和滤渣，滤渣继续煎煮1-2次；合并2-3次煎煮得到的煎出液即为决明子提取液；将决明子提取液采用现有的喷雾干燥技术进行处理，得到决明子提取物；
(2)将所述比例的蓝莓粉/越橘粉、叶黄素酯/叶黄素/叶黄素酯微囊粉、紫苏籽油粉/紫苏子油微囊粉、磷脂、瓜拉纳提取物、牛磺酸0.4、维生素C、维生素A/β胡萝卜素，与步骤(1)得到的决明子提取物混合均匀，即得到所述的预防和治疗视疲劳的组合物。
本发明还提供一种上述的预防和治疗眼部疾病的组合物，在制备预防和治疗眼部疾病药物、保健品及食品方面的应用。
上述技术方案中，所述的眼部疾病指的是白内障、青光眼、老年黄斑变性、老花眼及眼干眼涩或痒痛等眼部疾病。
上述技术方案中，在制备成预防和治疗眼部疾病药物、保健品及食品时，将所述的预防和治疗眼部疾病的组合物与辅剂混合均匀；混合物按照本领域常规方法制备成颗粒剂、片剂或者胶囊剂。
上述技术方案中，在制备成预防和治疗眼部疾病药物、保健品及食品时，辅剂的质量百分比为30％～90％，余量为所述的预防和治疗眼部疾病的组合物。
上述技术方案中，所述的辅剂为食品添加剂、填充剂、崩解剂、润滑剂、粘合剂、矫味剂中的任意一种，或任意两种及以上以任意比例混合而成的混合物。
上述技术方案中，所述的食品添加剂、填充剂、崩解剂、润滑剂、粘合剂、矫味剂均为符合GB2760《食品安全国家标准食品添加剂使用标准》及《中国药典》药用辅料标准规定的常用药用辅料，如麦芽糊精、植脂末、微晶纤维素、羟丙基纤维素、硬脂酸镁、柠檬酸、甜菊糖苷、阿斯巴甜中的一种或两种及以上以任意比例混合而成的混合物。
本发明技术方案的优点在于：本发明的组合物通过上述几种原料的配伍，通过多种作用基理发挥功效，并且在多种功效之间产生协同效应，有效作用于机体，在抗氧化、清除自由基、抑制炎症等各方面都具有显著效果，可以用于预防和治疗各类眼部疾病。
具体实施方式
以下对本发明技术方案的具体实施方式详细描述，但本发明并不限于以下描述内容：
本发明实施例中的食品添加剂、填充剂、崩解剂、润滑剂、粘合剂、矫味剂均为符合GB2760《食品安全国家标准食品添加剂使用标准》及《中国药典》药用辅料标准规定的常用药用辅料，如麦芽糊精、植脂末、微晶纤维素、羟丙基纤维素、硬脂酸镁、柠檬酸、甜菊糖苷、阿斯巴甜中的一种或两种以上的混合物。
以上原料均为现有的市售产品，例如决明子可购自河北华都药业有限公司，叶黄素酯、紫苏籽油可购自大连医诺股份有限公司，其余原料可购自北京天竹鸟食品添加剂有限公司。
下面结合具体的实施例对本发明的组合物进行具体的描述：
实施例1：
一种预防和治疗眼部疾病的颗粒剂，按照下述方法制备而成：
(1)准确称量：决明子30kg、越橘粉20kg、叶黄素15kg、紫苏籽微囊粉15kg、磷脂10kg、瓜拉纳提取物9.5kg、牛磺酸0.4kg、维生素C 0.195kg、β胡萝卜素0.005kg、植脂末27kg、麦芽糊精50kg；
(2)将30kg决明子放于10倍水中，在75℃左右下煎煮20min，过滤得到煎出液和滤渣，滤渣继续煎煮1次；合并2次煎煮得到的煎出液即为决明子提取液；将决明子提取液采用现有的喷雾干燥技术进行处理得到决明子提取物；
(3)将20kg越橘粉、15kg叶黄素、15kg紫苏籽微囊粉、10kg磷脂、9.5kg瓜拉纳提取物、0.4kg牛磺酸、0.195kg维生素C、0.005kgβ胡萝卜素分别过80目筛后，与步骤(1)得到的决明子提取物混合，混合20min后得到预防和治疗眼部疾病的组合物；
(4)将27kg植脂末、50kg麦芽糊精分别过80目筛后，与步骤(3)得到的预防和治疗眼部疾病的组合物进行混合，混合20min后得到的混合物采用现有的一步制粒法制粒、整粒，即得预防和治疗眼部疾病的颗粒剂；将所制得的颗粒分装成5g/袋，共30000袋。
人体推荐量为每人(成人)每天1次，每次1袋。
实施例2：
一种预防和治疗眼部疾病的胶囊剂，按照下述方法制备而成：
(1)准确称量：决明子20kg、蓝莓粉25kg、叶黄素酯25kg、紫苏子油粉20kg、磷脂5kg、瓜拉纳提取物4.5kg、牛磺酸0.5kg、维生素C 0.095kg、维生素A 0.005kg、植脂末28kg、麦芽糊精60kg；
(2)将20kg决明子放于10倍水中，在75℃左右下煎煮15min，过滤得到煎出液和滤渣，滤渣继续煎煮2次；合并3次煎煮得到的煎出液即为决明子提取液；将决明子提取液采用现有的喷雾干燥技术进行处理得到决明子提取物；
(3)将25kg蓝莓粉、25kg叶黄素、20kg紫苏子油粉、5kg磷脂、4.5kg瓜拉纳提取物、0.5kg牛磺酸、0.095kg维生素C、0.005kg维生素A分别过80目筛后，与步骤(1)得到的决明子提取物混合，混合20min后得到预防和治疗眼部疾病的组合物；
(4)将28kg植脂末、60kg麦芽糊精分别过80目筛后，与步骤(3)得到的预防和治疗眼部疾病的组合物进行混合，混合20min后得到的混合物采用现有的一步制粒法制粒、整粒；将所制得的颗粒用全自动胶囊灌装机制得400mg/粒的胶囊40万粒，即得预防和治疗视眼部疾病的胶囊剂。
人体推荐量为每人(成人)每天3次，每次4粒。
实施例3：
一种预防和治疗眼部疾病的片剂，按照下述方法制备而成：
(1)准确称量：决明子25kg、蓝莓粉20kg、叶黄素酯微囊粉15kg、紫苏籽油粉25kg、磷脂8kg、瓜拉纳提取物6.5kg、牛磺酸0.4kg、维生素C 0.995kg、维生素A0.005kg、植脂末14kg、麦芽糊精30kg；
(2)将25kg决明子放于10倍水中，在80℃左右下煎煮15min，过滤得到煎出液和滤渣，滤渣继续煎煮1次；合并2次煎煮得到的煎出液即为决明子提取液；将决明子提取液采用现有的喷雾干燥技术进行处理得到决明子提取物；
(3)将20kg蓝莓粉、15kg叶黄素酯微囊粉、25kg紫苏籽油粉、8kg磷脂、6.5kg瓜拉纳提取物、0.4kg牛磺酸、0.995kg维生素C、0.005kg维生素A分别过80目筛后，与步骤(2)得到的决明子提取物混合，混合20min后得到预防和治疗眼部疾病的组合物；
(4)将14kg植脂末、30kg麦芽糊精分别过80目筛后，与步骤(3)得到的预防和治疗眼部疾病的组合物进行混合，混合20min后得到的混合物采用现有的一步制粒法制粒、整粒；将所制得的颗粒用全自压片机制得600mg/片的片剂20万片，即得预防和治疗眼部疾病的片剂。
人体推荐量为每人(成人)每天2次，每次4片。
本发明的组合物通过上述几种原料的配伍，通过多种作用基理发挥功效，并且在多种功效之间产生协同效应，有效作用于机体，在抗氧化、清除自由基、抑制炎症等各方面都具有显著效果，可以用于预防和治疗各类眼部疾病。其以上功能可由以下实验证明。
动物实验一：
本实验通过Fenton反应模型产生大量自由基造成晶状体的氧化损伤，并测定晶状体酶性和非酶性抗氧化指标的变化，以及丙二醛(MDA)和总抗氧化能力(TAO)的变化来探讨本发明产品的抗氧化作用以及对晶状体氧化损伤的抑制作用。
1材料与方法
1.1材料
健康两性新西兰白兔9只(18眼)，体重1.7～2.2kg，由广东省医学实验动物中心提供，实验动物生产许可证号:SCXK(粤)2013-0002。
实验仪器采用二氧化碳培养箱(日本SANYO公司)，紫外/可见分光光度计(美国Beckman公司)，低温超速离心机(上海离心机厂)，超净工作台，手术显微镜，微量电子天平等。
Medium199购自上海芃硕生物科技有限公司；分析纯H2O2购自上海昊化化工有限公司，FeCl3购自上海江莱生物科技有限公司；可溶性蛋白(SP)试剂盒超氧化物歧化酶(SOD)、谷胱甘肽过氧化物酶(GSH-Px)、谷胱甘肽(GSH)、总抗氧化能力(TAO)、丙二醛(MDA)试剂盒购自上海润裕生物科技有限公司。
1.2方法
1.2.1供试品按本发明实施例一制得成品，人体推荐量为每人(成人)每日5g，试验剂量为272.5mg/kg。取供试品5.45mg加10mL蒸馏水溶解备用。
1.2.2实验分组与培养液制备
将9只兔(18只眼)随机分成3组。对照组：Medium199 10mL+青霉素及链霉素各300U；Fenton组：对照组培养液+30％H2O2 0.1mL+FeC13 2mg；实验组：Fenton组培养液+供试品1mL。各组培养液均于实验开始时在超净工作台中配制并分装入培养板中备用。
1.2.3兔晶状体制备
把兔逐只固定于兔盒内并局部麻醉后，无菌操作摘出眼球。立即将眼球用75％酒精浸浴3min，冰浴下生理盐水漂洗后，在手术显微镜下剪除角膜，撕去虹膜，剪断悬韧带，游离晶状体，用晶状体圈匙小心托出完整的晶状体。去净玻璃体，迅速用电子天平称取晶状体重量并记录后，将晶状体按上述分组分别置入已装有培养液的培养板中。置37℃,5％CO2与95％空气的二氧化碳培养箱中温育4h。
1.2.4晶状体匀浆制备
将晶状体用0～4℃PBS充分冲洗，再用滤纸吸干后，置入含5mL0～4℃PBS的匀浆器内，冰浴下充分研磨5min制成匀浆。
1.2.5指标测定
将晶状体匀浆用低温高速离心机10000rpm离心15min，取上清液，测定以下指标：双缩脲法测定晶状体SP；羟胺法测定SOD；二硫代二硝基苯甲酸法测定GSH-Px和GSH；Fe3+还原法测定TAO；硫代巴比妥酸法测定MDA。上述测定步骤均严格按试剂盒说明操作。
1.2.6统计处理数据以；表示，用SPSS统计程序对结果进行两组t检验。
2.结果
2.1对晶状体可溶性蛋白及抗氧化酶的影响见表1。
表1对晶状体可溶性蛋白和抗氧化酶及谷胱甘肽的影响
注：与Fenton组比较△(P＜0.05)、△△(P＜0.01)。
2.2对晶状体TAO水平和MDA的影响见表2。
表2对晶状体TAO水平和MDA影响
注：与Fenton组比较△△(P＜0.01)。
2.3结论
从表1可见：本发明实验组对晶状体SOD、GSH-Px活性、GSH含量均显著高于Fenton组(P＜0.01)，MDA含量均显著低于Fenton组(P＜0.01)，TAO水平显著高于Fenton组(P＜0.01)，表明本发明产品对离体氧化损伤的眼晶状体有不同程度的防护作用，对眼部的抗氧化作用显著。
上述实例只是为说明本发明的技术构思以及技术特点，并不能以此限制本发明的保护范围。凡根据本发明的实质所做的等效变换或修饰，都应该涵盖在本发明的保护范围之内。
Claims (9)
1.一种预防和治疗眼部疾病的组合物，其特征在于，每100重量份包括以下重量份的原料：
决明子10-40份、蓝莓粉/越橘粉5-30份、叶黄素酯/叶黄素/叶黄素酯微囊粉10-30份、紫苏籽油粉/紫苏子油微囊粉10-30份、磷脂1-15份、瓜拉纳提取物1-15份、牛磺酸0.1-3份、维生素C 0.01-0.5份、维生素A/β胡萝卜素0.001-0.1份。
2.根据权利要求1所述的预防和治疗眼部疾病的组合物，其特征在于，每100重量份包括以下重量份的原料：
决明子30份、蓝莓粉/越橘粉20份、叶黄素酯/叶黄素/叶黄素酯微囊粉15份、紫苏籽油粉/紫苏子油微囊粉15份、磷脂10份、瓜拉纳提取物9.5份、牛磺酸0.4份、维生素C 0.195份、维生素A/β胡萝卜素0.005份。
3.权利要求1、2任一项所述的预防和治疗眼部疾病的组合物的制备方法，其特征在于，包括以下步骤：
(1)将所述比例的决明子放于6-15倍水中，在70-95℃下煎煮10-30min，过滤得到煎出液和滤渣，滤渣继续煎煮1-2次；合并2-3次煎煮得到的煎出液即为决明子提取液；将决明子提取液采用现有的喷雾干燥技术进行处理，得到决明子提取物；
(2)将所述比例的蓝莓粉/越橘粉、叶黄素酯/叶黄素/叶黄素酯微囊粉、紫苏籽油粉/紫苏子油微囊粉、磷脂、瓜拉纳提取物、牛磺酸0.4、维生素C、维生素A/β胡萝卜素，与步骤(1)得到的决明子提取物混合均匀，即得到所述的预防和治疗视疲劳的组合物。
4.权利要求1、2任一项所述的预防和治疗眼部疾病的组合物在制备预防和治疗眼部疾病药物、保健品及食品方面的应用。
5.根据权利要求4所述的应用，其特征在于，所述的眼部疾病指的是白内障、青光眼、老年黄斑变性、老花眼及眼干眼涩或痒痛等眼部疾病。
6.根据权利要求4所述的应用，其特征在于，在制备成预防和治疗眼部疾病药物、保健品及食品时，将所述的预防和治疗眼部疾病的组合物与辅剂混合均匀；混合物按照本领域常规方法制备成颗粒剂、片剂或者胶囊剂。
7.根据权利要求6所述的应用，其特征在于，在制备成预防和治疗眼部疾病药物、保健品及食品时，辅剂的质量百分比为30％～90％，余量为所述的预防和治疗眼部疾病的组合物。
8.根据权利要求7所述的应用，其特征在于，所述的辅剂为食品添加剂、填充剂、崩解剂、润滑剂、粘合剂、矫味剂中的任意一种，或任意两种及以上以任意比例混合而成的混合物。
9.根据权利要求8所述的应用，所述的辅剂指的是麦芽糊精、植脂末、微晶纤维素、羟丙基纤维素、硬脂酸镁、柠檬酸、甜菊糖苷、阿斯巴甜中的任意一种，两种以上及以上以任意比例混合而成的混合物。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710696456.XA CN107375505A (zh) | 2017-08-15 | 2017-08-15 | 一种预防和治疗眼部疾病的组合物及其制备方法与应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710696456.XA CN107375505A (zh) | 2017-08-15 | 2017-08-15 | 一种预防和治疗眼部疾病的组合物及其制备方法与应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107375505A true CN107375505A (zh) | 2017-11-24 |
Family
ID=60354681
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710696456.XA Pending CN107375505A (zh) | 2017-08-15 | 2017-08-15 | 一种预防和治疗眼部疾病的组合物及其制备方法与应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107375505A (zh) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108524667A (zh) * | 2018-05-23 | 2018-09-14 | 南京中生生物科技有限公司 | 一种具有缓解视疲劳作用的叶黄素酯组合物及其制备方法 |
| CN109549947A (zh) * | 2019-01-25 | 2019-04-02 | 广州中健健康科技有限公司 | 一种抗蓝光的眼部喷剂及其制备方法 |
| CN110338410A (zh) * | 2019-08-14 | 2019-10-18 | 郑州福盛康眼科医疗技术有限公司 | 一种眼部保健品及其制备方法 |
| CN110711246A (zh) * | 2019-11-20 | 2020-01-21 | 大连迪麦医疗科技有限公司 | 一种改善眼部疲劳及疾病的抗氧化组合物富氢水喷雾及其制备方法 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101766307A (zh) * | 2010-03-02 | 2010-07-07 | 中国农业科学院油料作物研究所 | 一种具有缓解视疲劳作用的保健食品及其制备方法 |
| CN102550912A (zh) * | 2011-12-27 | 2012-07-11 | 北京康比特体育科技股份有限公司 | 一种提神醒脑的组合物 |
| CN106138199A (zh) * | 2016-07-29 | 2016-11-23 | 青岛尚医制药有限公司 | 一种提供眼睛营养保护视力的复合配方及其制备方法 |
| CN106265883A (zh) * | 2015-05-19 | 2017-01-04 | 李萍 | 一种改善飞蚊症、玻璃体混浊、黄斑变性、青光眼、白内障及眼干、眼涩、眼疲劳的配方 |
-
2017
- 2017-08-15 CN CN201710696456.XA patent/CN107375505A/zh active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101766307A (zh) * | 2010-03-02 | 2010-07-07 | 中国农业科学院油料作物研究所 | 一种具有缓解视疲劳作用的保健食品及其制备方法 |
| CN102550912A (zh) * | 2011-12-27 | 2012-07-11 | 北京康比特体育科技股份有限公司 | 一种提神醒脑的组合物 |
| CN106265883A (zh) * | 2015-05-19 | 2017-01-04 | 李萍 | 一种改善飞蚊症、玻璃体混浊、黄斑变性、青光眼、白内障及眼干、眼涩、眼疲劳的配方 |
| CN106138199A (zh) * | 2016-07-29 | 2016-11-23 | 青岛尚医制药有限公司 | 一种提供眼睛营养保护视力的复合配方及其制备方法 |
Non-Patent Citations (2)
| Title |
|---|
| 王彩萍: "决明子对老龄大鼠晶状体抗氧化作用的有效活性部位研究", 《山西中医学院学报》 * |
| 黄秀榕等: "天然抗氧化剂对抗晶状体氧化损伤作用的实验研究", 《中国病理生理杂志》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108524667A (zh) * | 2018-05-23 | 2018-09-14 | 南京中生生物科技有限公司 | 一种具有缓解视疲劳作用的叶黄素酯组合物及其制备方法 |
| CN109549947A (zh) * | 2019-01-25 | 2019-04-02 | 广州中健健康科技有限公司 | 一种抗蓝光的眼部喷剂及其制备方法 |
| CN110338410A (zh) * | 2019-08-14 | 2019-10-18 | 郑州福盛康眼科医疗技术有限公司 | 一种眼部保健品及其制备方法 |
| CN110711246A (zh) * | 2019-11-20 | 2020-01-21 | 大连迪麦医疗科技有限公司 | 一种改善眼部疲劳及疾病的抗氧化组合物富氢水喷雾及其制备方法 |
| CN110711246B (zh) * | 2019-11-20 | 2023-04-14 | 大连迪麦医疗科技有限公司 | 一种改善眼部疲劳及疾病的抗氧化组合物富氢水喷雾及其制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107375505A (zh) | 一种预防和治疗眼部疾病的组合物及其制备方法与应用 | |
| CN109091675B (zh) | 一种复方低浓度阿托品类药物滴眼液及其制备方法 | |
| CN103417733B (zh) | 一种缓解视疲劳的药物组合物 | |
| CN104225265B (zh) | 一种缓解视力疲劳的中药组合物 | |
| WO2008083513A1 (fr) | Extrait de pellicule de soja noir et procédé de préparation et d'utilisation de cet extrait | |
| CN106038612A (zh) | 一种保护眼睛视力的药物组合物及其制备方法和应用 | |
| CN105851998A (zh) | 一种抗氧化软胶囊及其制备方法 | |
| CN104824675A (zh) | 视力改善叶黄素胶囊 | |
| CN102166203A (zh) | 一种缓解视疲劳眼贴及其制备方法 | |
| CN100486456C (zh) | 一种用于缓解视疲劳的保健食品及其制备方法 | |
| CN104688760B (zh) | 一种由柴胡皂苷a和牛磺酸组成的药物组合物及其用途 | |
| EP3275457B1 (en) | Pharmaceutical composition comprising silybin and pu'er tea essence | |
| CN104887781B (zh) | 一种用于缓解干眼症的眼药水及其制备方法 | |
| CN105983004A (zh) | 一种缓解视疲劳的组合物和制备方法 | |
| CN101757299A (zh) | 一种缓解视疲劳产品及其制备方法 | |
| CN101361892B (zh) | 一种用于治疗白内障的中药制剂及其制备方法 | |
| CN108434166B (zh) | 一种血塞通药物组合物及其制备方法、制剂与应用 | |
| CN110742917A (zh) | 沙棘油组合物及含有其的药品和保健品 | |
| CN110787211A (zh) | 人参洗眼液及其制备方法 | |
| KR20170019399A (ko) | 인삼 열매 추출물을 함유하는 퇴행성 신경장애 치료용 조성물 | |
| CN105147709B (zh) | 一种替诺福韦二吡呋酯或其药用盐的用途 | |
| CN105327342B (zh) | 一种治疗皮肤湿疹和虫咬皮炎的膏剂及其制备方法 | |
| CN105055248B (zh) | 远志总皂苷在制备皮肤抗衰老日化产品中的应用及其制备的抗衰老日化产品 | |
| EP3181143A1 (en) | Use of cistanche tubulosa extract in the preparation of drugs or foods for protecting ocular cells | |
| CN105983006A (zh) | 一种缓解视疲劳的组合物及制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171124 |